HBHector Biliran

Hector Biliran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hector Biliran has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Renwei Chen

    Marine Science Institute, University of California Santa Barbara, Santa Barbara, CA, U.S.A.

    8 shared publications
  • Xin Yao

    Department of Biology, Xavier University of Louisiana, New Orleans, LA, U.S.A.

    8 shared publications
  • Shubha Kale Ireland

    Department of Biological and Public Health Sciences, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA 70125, United States

    7 shared publications
  • Tri Pham

    Department of Biological and Public Health Sciences, Xavier University of Louisiana, 1 Drexel Drive, New Orleans, LA 70125, United States; Department of Pathology, Wayne State University, Detroit, MI 48201, United States

    6 shared publications
  • Brandi Temple

    Department of Biological and Public Health Sciences, Xavier University of Louisiana, New Orleans, LA 70125, USA

    4 shared publications
  • Erkki Ruoslahti

    ‡Center for Nanomedicine, Sanford-Burnham Medical Research Institute, 1105 Life Sciences Technology Bldg, University of California, Santa Barbara, CA 93106

    3 shared publications

Latest Publications

  • BIT1 as an Effector of EGFR-TKI-induced Apoptosis via TLE1 Inhibition in Lung Adenocarcinoma Cells

    by Ma Carmela Dela Cruz, Xin Yao, Alajah Nealy, James Bailey, Micah Nalls, Paul Mark Medina, Renwei Chen, Hector Biliran

    Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) remains a substantial clinical obstacle in treating lung adenocarcinoma (LUAD). Identifying pro-survival pathways that allow tumor cells to evade TKI-induced apoptosis is critical for overcoming this resistance. The transcriptional repressor transducin-like enhancer of split 1 (TLE1) was previously identified as a crucial oncogenic factor that promotes survival in resistant cells. This study investigates the mitochondrial protein Bcl-2 inhibitor of transcription 1 (Bit1) as a key pro-apoptotic signal that overrides the TLE1-mediated survival program. EGFR-TKI sensitive, resistant, and drug-tolerant persister LUAD models were utilized. Bit1 release and TLE1 translocation were assessed via subcellular fractionation. Cell fate following genetic manipulation was determined through viability and apoptosis assays, while RNA-sequencing identified TLE1-regulated transcriptional changes. In sensitive EGFR-mutant non-small cell lung cancer (NSCLC) cells, TKI treatment triggers the rapid cytosolic release of the mitochondrial outer membrane permeabilization (MOMP)-tethered protein Bit1. This early mobilization precedes cytochrome C release and occurs independently of full MOMP, identifying the Bit1 pathway as a novel, early-response death signal in lung cancer. While Bit1 downregulation attenuated EGFR-TKI-induced apoptosis in EGFR-mutant lung adenocarcinoma cells, ectopic mitochondrial Bit1 expression restored TKI sensitivity in resistant cells. Mechanistically, TKI exposure triggered cytosolic Bit1-AES complex formation, resulting in the nuclear exclusion and sequestration of TLE1. This axis is also pivotal in adaptive resistance; TLE1 was upregulated in drug-tolerant persister (DTP) cells and required for their survival, while Bit1 activation attenuated DTP formation. Transcriptomic analysis revealed that TLE1 coordinates a resistance program enriched for EMT and Notch signaling. The Bit1/TLE1 axis is a pivotal regulatory switch dictating apoptotic outcomes following EGFR-TKI treatment. This mechanism identifies a therapeutic vulnerability, suggesting that pharmacological Bit1 pathway activation could be an effective strategy to overcome acquired resistance in LUAD.


  • Open Access

    TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition

    by Ma Carmela Dela Cruz, Xin Yao, Nasir Roberts, Prince Iheukwumere, Alana Carmouche, Paul Mark Medina, Hector Biliran


  • Open Access

    TLE1 corepressor promotes gefitinib resistance in lung cancer A549 cells via E‑cadherin silencing

    by Xin Yao, Nasir Roberts, Prince Iheukwumere, Alana Carmouche, Renwei Chen, Ma. Carmela Dela Cruz, Hector Biliran

    As a putative lung specific oncogene, the transducin‑like enhancer of split 1 (TLE1) corepressor drives an anti‑apoptotic and pro‑epithelial‑mesenchymal transition (EMT) gene transcriptional programs in human lung adenocarcinoma (LUAD) cells, thereby promoting anoikis resistance and tumor aggressiveness. Through its survival‑ and EMT‑promoting gene regulatory programs, TLE1 may impact drug sensitivity and resistance in lung cancer cells. In the present study, a novel function of TLE1 was uncovered as an inhibitor of the antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI) gefitinib in the human LUAD cell line A549, which exhibits moderate sensitivity to EGFR‑TKI. While upregulation of TLE1 expression potently inhibited the proliferation inhibitory and apoptotic effects of gefitinib in A549 cells, downregulation of endogenous TLE1 in these cells enhanced their sensitivity to gefitinib. In experimentally derived gefitinib‑resistant A549 cells (A549GR) that have acquired EMT, TLE1 expression is upregulated as compared with parental A549 cells, and acute ablation of TLE1 expression is sufficient to partially restore gefitinib sensitivity and attenuate EMT phenotype. Mechanistic studies showed that TLE1 confers gefitinib resistance in A549 cells in part via downregulation of E‑cadherin, a known potentiator of EGFR‑TKI sensitivity and apoptosis induction. Importantly, the TLE1/E‑cadherin transcriptional axis is negatively regulated by gefitinib to trigger apoptosis via the Bcl‑2‑inhibitor of transcription 1 cell death pathway. In conclusion, these results indicate a novel role of TLE1 in modulating EGFR‑TKI sensitivity in lung cancer cells via regulation of E‑cadherin expression, and its upregulation may potentiate EGFR‑TKI resistance in LUAD.


  • Downregulation of Bit1 expression promotes growth, anoikis resistance, and transformation of immortalized human bronchial epithelial cells via Erk activation-dependent suppression of E-cadherin

    by Xin Yao, Selena Gray, Tri Pham, Mychael Delgardo, An Nguyen, Stephen Do, Shubha Kale Ireland, Renwei Chen, Asim B. Abdel-Mageed, Hector Biliran


  • Open Access

    TLE1 inhibits anoikis and promotes tumorigenicity in human lung cancer cells through ZEB1-mediated E-cadherin repression

    by Xin Yao, Tri Pham, Brandi Temple, Selena Gray, Cornita Cannon, Camry Hardy, Kamari Fletcher, Shubha Kale Ireland, Ahamed Hossain, Renwei Chen, et al.

    TLE1 inhibits anoikis and promotes tumorigenicity in human lung cancer cells through ZEB1-mediated E-cadherin repression TLE1 inhibits anoikis and promotes tumorigenicity in human lung cancer cells through ZEB1-mediated E-cadherin repression


  • Open Access

    The Anoikis Effector Bit1 Inhibits EMT through Attenuation of TLE1-Mediated Repression of E-Cadherin in Lung Cancer Cells

    by Xin Yao, Tri Pham, Brandi Temple, Selena Gray, Cornita Cannon, Renwei Chen, Asim B Abdel-Mageed, Hector Biliran

    The mitochondrial Bcl-2 inhibitor of transcription 1 (Bit1) protein is part of an anoikis-regulating pathway that is selectively dependent on integrins. We previously demonstrated that the caspase-independent apoptotic effector Bit1 exerts tumor suppressive function in lung cancer in part by inhibiting anoikis resistance and anchorage-independent growth in vitro and tumorigenicity in vivo. Herein we show a novel function of Bit1 as an inhibitor cell migration and epithelial–mesenchymal transition (EMT) in the human lung adenocarcinoma A549 cell line. Suppression of endogenous Bit1 expression via siRNA and shRNA strategies promoted mesenchymal phenotypes, including enhanced fibroblastoid morphology and cell migratory potential with concomitant downregulation of the epithelial marker E-cadherin expression. Conversely, ectopic Bit1 expression in A549 cells promoted epithelial transition characterized by cuboidal-like epithelial cell phenotype, reduced cell motility, and upregulated E-cadherin expression. Specific downregulation of E-cadherin in Bit1-transfected cells was sufficient to block Bit1-mediated inhibition of cell motility while forced expression of E-cadherin alone attenuated the enhanced migration of Bit1 knockdown cells, indicating that E-cadherin is a downstream target of Bit1 in regulating cell motility. Furthermore, quantitative real-time PCR and reporter analyses revealed that Bit1 upregulates E-cadherin expression at the transcriptional level through the transcriptional regulator Amino-terminal Enhancer of Split (AES) protein. Importantly, the Bit1/AES pathway induction of E-cadherin expression involves inhibition of the TLE1-mediated repression of E-cadherin, by decreasing TLE1 corepressor occupancy at the E-cadherin promoter as revealed by chromatin immunoprecipitation assays. Consistent with its EMT inhibitory function, exogenous Bit1 expression significantly suppressed the formation of lung metastases of A549 cells in an in vivo experimental metastasis model. Taken together, our studies indicate Bit1 is an inhibitor of EMT and metastasis in lung cancer and hence can serve as a molecular target in curbing lung cancer aggressiveness.


  • TLE1 promotes EMT in A549 lung cancer cells through suppression of E-cadherin

    by Xin Yao, Shubha Kale Ireland, Tri Pham, Brandi Temple, Renwei Chen, Madhwa H.G. Raj, Hector Biliran


  • Open Access

    The Anoikis Effector Bit1 Displays Tumor Suppressive Function in Lung Cancer Cells

    by Xin Yao, Scott Jennings, Shubha Kale Ireland, Tri Pham, Brandi Temple, Mya Davis, Renwei Chen, Ian Davenport, Hector Biliran

    The mitochondrial Bit1 (Bcl-2 inhibitor of transcription 1) protein is a part of an apoptotic pathway that is uniquely regulated by integrin-mediated attachment. As an anoikis effector, Bit1 is released into the cytoplasm following loss of cell attachment and induces a caspase-independent form of apoptosis. Considering that anoikis resistance is a critical determinant of transformation, we hypothesized that cancer cells may circumvent the Bit1 apoptotic pathway to attain anchorage-independence and tumorigenic potential. Here, we provide the first evidence of the tumor suppressive effect of Bit1 through a mechanism involving anoikis induction in human lung adenocarcinoma derived A549 cells. Restitution of Bit1 in anoikis resistant A549 cells is sufficient to induce detachment induced-apoptosis despite defect in caspase activation and impairs their anchorage-independent growth. Conversely, stable downregulation of Bit1 in these cells significantly enhances their anoikis resistance and anchorage-independent growth. The Bit1 knockdown cells exhibit significantly enhanced tumorigenecity in vivo. It has been previously shown that the nuclear TLE1 corepressor is a putative oncogene in lung cancer, and we show here that TLE1 blocks Bit1 mediated anoikis in part by sequestering the pro-apoptotic partner of Bit1, the Amino-terminal Enhancer of Split (AES) protein, in the nucleus. Taken together, these findings suggest a tumor suppressive role of the caspase-independent anoikis effector Bit1 in lung cancer. Consistent with its role as a tumor suppressor, we have found that Bit1 is downregulated in human non-small cell lung cancer (NSCLC) tissues.


  • Bit1 in anoikis resistance and tumor metastasis

    by Scott Jenning, Tri Pham, Shubha Kale Ireland, Erkki Ruoslahti, Hector Biliran


  • TLE1 Is an Anoikis Regulator and Is Downregulated by Bit1 in Breast Cancer Cells

    by Chris Brunquell, Hector Biliran, Scott Jennings, Shubha Kale Ireland, Renwei Chen, Erkki Ruoslahti

    TLE1 is a Groucho-related transcriptional repressor protein that exerts survival and antiapoptotic function in several cellular systems and has been implicated in the pathogenesis of cancer. In the present study, we found that TLE1 is a regulator of anoikis in normal mammary epithelial and breast carcinoma cells. The induction of apoptosis following loss of cell attachment to the extracellular matrix (anoikis) in untransformed mammary epithelial MCF10A cells was associated with significant downregulation of TLE1 expression. Forced expression of exogenous TLE1 in these cells promoted resistance to anoikis. In breast cancer cells, TLE1 expression was significantly upregulated following detachment from the extracellular matrix. Genetic manipulation of TLE1 expression via overexpression and downregulation approaches indicated that TLE1 promotes the anoikis resistance and anchorage-independent growth of breast carcinoma cells. Mechanistically, we show that TLE1 inhibits the Bit1 anoikis pathway by reducing the formation of the proapoptotic Bit1-AES complex in part through sequestration of AES in the nucleus. The mitochondrial release of Bit1 during anoikis as well as exogenous expression of the cytoplasmic localized Bit1 or its cell death domain induced cytoplasmic translocation and degradation of nuclear TLE1 protein. These findings indicate a novel role for TLE1 in the maintenance of anoikis resistance in breast cancer cells. This conclusion is supported by an immunohistochemical analysis of a breast cancer tissue array illustrating that TLE1 is selectively upregulated in invasive breast tumors relative to noninvasive ductal carcinoma in situ and normal mammary epithelial tissues. Mol Cancer Res; 10(11); 1482–95. ©2012 AACR.